ELI LILLY Aktie

 

Dave Ricks hat Eli Lilly zum wertvollsten Pharmakonzern der Welt gemacht. Im Interview kritisiert er die Bundesregierung scharf – und gibt ein Versprechen ab....

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks....

The company is constantly thinking big....

INDIANAPOLIS (dpa-AFX) - On Thursday, Eli Lilly and Company (LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing that Foundayo was associated with significant reductions in pre......

Lilly's "Incredible Hulk" Obesity Combo Delivers Record 23% Weight Loss In Diabetics Eli Lilly's experimental combination of eloralintide and Mounjaro delivered average weight loss of up to 23% in people with diabetes, strengthening the company's competitive edge against Novo Nordisk in the obesity and diabetes treatment market. Participants who received the highest dose lost an average of 54 pounds over 48 weeks. Their A1C, a measure of average blood sugar, fell 2.9 percentage points from a baseline of 8.1%, with up to three-quarters reaching normal blood sugar levels, according to Bloomberg. "This could open up even a next frontier in weight loss," Ken Custer, president of Lilly's cardiometabolic unit, stated. Custer said the study sets a "new, even higher bar" but cautioned against comparing different studies. Lilly shares rose as much as 2.6% earlier today before paring gains. Year to date, shares are up a little more than 10%, while competitor Novo Nordisk has slumped more than 20%. T...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Christian Angermayer verkauft Atai an Eli Lilly. Der Deal könnte bis zu 3,8 Milliarden Dollar wert sein. Im Interview spricht er auch über KI und seine aktuellen Wetten....

INDIANAPOLIS (dpa-AFX) - Wednesday. Eli Lilly and Company (LLY) reported detailed results from the Phase 3 ACHIEVE-4 trial showing that Foundayo (orforglipron) demonstrated cardiovascular safety a......

In the most recent trading session, Eli Lilly (LLY) closed at $1, indicating a -2.33% shift from the previous trading day....

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results....

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said on Wednesday that its investigational EloraTZP combination of eloralintide and tirzepatide delivered substantial weight loss and reduction......

Roche is increasingly looking like a notable contender in this fast-growing area....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Eli Lilly & Co. said a new drug combination helped people with diabetes lose as much as 23% of their weight, more than other medicines in similar studies, suggesting it has the potential to be the drugmaker's strongest obesity shot to date....

CNBC's Annika Kim Constantino reports on Eli Lilly's new combo regiment showed stronger weight loss results than the company's existing obesity drug....

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year. ...

INDIANAPOLIS (dpa-AFX) - Eli Lilly (LLY) said EBGLYSS (lebrikizumab-lbkz) met the primary and secondary endpoints in the Phase 3b ADtouch study, showing significant improvements in skin clearance,......

Eli Lilly hat unlängst die Pole-Position im Adipositas-Markt erobert und Novo (vormals Novo Nordisk) vom Thron gestoßen. Das Duopol gibt weiter den Takt vor, doch zahlreiche andere Wirkstoffkandidaten von konkurrierenden Unternehmen nähern sich späteren Studienphasen....